

Serial No: 10/775,444  
Filing Date: February 10, 2004

## AMENDMENTS TO THE CLAIMS

RECEIVED  
CENTRAL FAX CENTER  
DEC 05 2008

Listing of Claims

This listing of claims will replace all prior versions, and listing, of claims in the present application.

1. (Currently amended) A method for the treatment of a disorder wherein ~~said disorder is selected from the group consisting of multiple myeloma, liquid tumor, liver cancer, thymus disorder, T-cell mediated autoimmune disease, endocrinological disorder, ischemia, and neurodegenerative disorder~~ in a mammal comprising administering to said mammal an effective amount of a human anti-IGF-IR antibody ~~that is effective in treating said disorder, in combination with an agent selected from the group consisting of a corticosteroid, anti-emetic, cancer vaccine, analgesic, anti-vascular agent, and anti-proliferative agent, wherein the antibody is 2.13.2.~~

2. (Cancelled)

3. (Cancelled)

4. (Current amended) The method of claim 1 comprising administering said antibody in combination with an anti-emetic agent, wherein said anti-emetic agent is selected from the group consisting of ondansetron, hydrochloride, granisetron hydrochloride, metoclopramide, domperidone, haloperidol, cyclizine, lorazepam, prochlorperazine, dexamethasone, levomepromazine, or tropisetron.

5. (Original) The method of claim 1 comprising administering said antibody in combination with a vaccine, wherein said vaccine is selected from GM-CSF DNA and cell-based vaccines, dendritic cell vaccines, recombinant viral vaccines, heat shock protein (HSP) vaccines, allogeneic or autologous tumor vaccines.

6. (Current amended) The method of claim 1 comprising administering said antibody in combination with an analgesic agent, wherein said analgesic agent is selected from the group consisting of ibuprofen, naproxen, choline magnesium trisalicylate, or oxycodone hydrochloride.

Serial No: 10/775,444

Filing Date: February 10, 2004

7. (Current amended) The method of claim 1 comprising administering said antibody in combination with an anti-vascular agent, wherein said anti-vascular agent is selected from the group consisting of bevacizumab, or rhuMAb-VEGF.

8. (Current amended) The method of claim 1 comprising administering said antibody in combination with an anti-proliferative agent, wherein said anti-proliferative agent is selected from the group consisting of farnesyl protein transferase inhibitors,  $\alpha\beta 3$  inhibitors,  $\alpha\beta 5$  inhibitors, p53 inhibitors, and PDGFR inhibitors

9 – 17. (Cancelled)